ASSAY and Drug Development Technologies

About This Journal:

  • Print This Page
  • Subscribe to an RSS Feed

Sample Content

My Liebert Connect

Sign up to stay informed--receive email notifications for this journal

ASSAY and Drug Development Technologies

Editor-in-Chief: Bruce Melancon, PhD

ISSN: 1540-658X • Online ISSN: 1557-8127 • 8 Issues Annually

Current Volume: 16

Latest Impact Factor* is 2.196

*2016 Journal Citation Reports® (Clarivate Analytics, 2017)

Featured Press Releases and Editorial Content

  • New Quality Control Method to Select Effective Methyl-β-Cyclodextrin for Treating Neimann-Pick Disease...Read More
  • Discovery of New IRAP Inhibitors to Improve Cognitive Functions...Read More
  • High-throughput Screening Strategy Identifies Compounds Active Against Antibiotic-Resistant Bacteria...Read More


ASSAY and Drug Development Technologies delivers access to the techniques and tools that enable new advances in early-stage screening, and lead to therapeutic compounds for drug discovery and development. This authoritative, rapidly peer-reviewed journal features original papers, application-oriented technology reviews, and reports in methodology and technology application.

ASSAY and Drug Development Technologies coverage includes:

  • Assay design, target development, high-throughput technologies, and chemistry
  • Lab automation, sample management, bioinformatics, data mining, virtual screening, and data analysis
  • Approaches to assays configured for gene families, inherited, and infectious diseases
  • Assays and strategies for adapting model organisms to drug discovery
  • The use of stem cells as models of disease
  • Translation of phenotypic outputs to target identification
  • Exploration and mechanistic studies of the technical basis for assay and screening artifacts

The Journal also features a dedicated Drug Repurposing, Rescue, and Repositioning (DRRR) section in the journal. These special peer-reviewed collections of papers present techniques and tools for finding new uses for approved drugs – particularly for disorders where no animal model, physiologic abnormality, biochemical pathway, or molecular target has been identified.

This DRRR special section will feature original papers, application-oriented technology reviews, and reports in methodology and technology application to drug repurposing and redevelopment including:

  • Designing assays and interpreting output to enable alternate drug target identification
  • Pathway analysis and bioinformatics to identify and exploit drug promiscuity
  • In silico technologies to identify alternate drug targets
  • "Big Data" mining and side effect pattern analysis in clinical and healthcare repositories

ASSAY and Drug Development Technologies is under the editorial leadership of Editor-in-Chief Bruce Melancon, PhD, University of Notre Dame; and other leading investigators.The DRRR section is under the leadership of Hermann Mucke, PhD, of Hermann Mucke Pharma Consultancy e.U. View the entire editorial board.

ournal Audience Includes: Drug discovery and developmental scientists, pharmaceutical and biotechnology researchers, and disease foundation specialists, among others.


Indexed/Abstracted in:

MEDLINE; PubMed; PubMed Central; Science Citation Index Expanded; Biochemistry & Biophysics Citation Index®; BIOSIS Previews; Chemical Abstracts; Biological Abstracts; Journal Citation Reports/Social Sciences Edition; EMBASE/Excerpta Medica; Scopus; ProQuest databases

Come See Us!

The views, opinions, findings, conclusions and recommendations set forth in any Journal article are solely those of the authors of those articles and do not necessarily reflect the views, policy or position of the Journal, its Publisher, its editorial staff or any affiliated Societies and should not be attributed to any of them.

Recommended Publications

You may be interested in the following publications:

    Applied In Vitro Toxicology

    Applied In Vitro Toxicology

    A new peer-reviewed journal presenting applications of alternative in vitro testing methods for predicting adverse effects in the pharmaceutical, chemical, and personal care industries.



    Solely focused on disseminating the latest cutting-edge advances in the zebrafish as a model organism for the study of vertebrate development, with attention to other aquarium species including medaka, Fugu, and Xiphophorus.

    Genetic Engineering & Biotechnology News

    Genetic Engineering & Biotechnology News

    The mostly widely-read publication covering tools, techniques, and technologies in the biotechnology industry.

    Antioxidants & Redox Signaling

    Antioxidants & Redox Signaling

    The leading resource for the latest research and information on antioxidants and redox biology. The Journal explores key aspects of the important and expanding world of redox-based therapeutics.

    OMICS: A Journal of Integrative Biology

    OMICS: A Journal of Integrative Biology

    The only peer-reviewed interdisciplinary publication covering all "OMICS"-related science, such as integrative biology and medicine. The Journal also reports on all methods and resources underpinning integrative research.

    The CRISPR Journal

    The CRISPR Journal

    The CRISPR Journal delivers groundbreaking multidisciplinary research, advances, and commentary on CRISPR, the extraordinary technology that gives scientists the power to cure disease and sculpt evolution.

Browse All Publications »